Janssen Biotech, Inc. has licensed Ionis Pharmaceuticals’ IONIS-JBI1-2.5Rx, an oral antisense drug for the treatment of a GI autoimmune disease, for $10 million. Janssen will assume all global development, regulatory and commercialization responsibilities after Ionis completes the IND-enabling studies.   Ionis is eligible to receive as much as $800 million in development, regulatory and sales milestones and license fees for three programs, as well as royalties on sales from any product that is...